Clinical trials: Anger
Headache
A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.
To determine if the intravenous administration of Metoclopramide and diphenhydramine in combination can effectively treat headaches in pregnant patients in those refractory to acetaminophen when compared to codeine
- Trial name
- MAD (NCT02295280)
- Testing
- Metoclopramide, Diphenhydramine, Codeine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- St. Louis University
Alcohol Intoxication, Anger
Men, Mood, and Attention Study: Examination of Alcohol, State Anger, and Emotion Regulation Sexual Aggression
Given the public health and social relevance of sexual aggression and the gap in the extant literature regarding state anger, emotion regulation, alcohol, and sexual aggression, the present study will contribute to our…
- Trial name
- MMA (NCT04192448)
- Testing
- Alcohol Administration, Mood Induction
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Elizabeth C Neilson
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
HIV Infections
Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled, FTIH study, that includes both single-ascending and multiple-ascending dose phase to assess the safety, tolerability, and…
- Trial name
- NCT03984812
- Testing
- GSK3732394
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis B
First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects
This study is a Phase 1, randomized, double-blind (Sponsor unblinded), placebo controlled, dose escalation study to determine the safety, tolerability and pharmacokinetics (PK) profile of GSK3389404 as single (Part 1) and…
- Trial name
- NCT02647281
- Testing
- GSK3389404
- Where
- 2 sites in United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Aggression, Anger
Group CBT for Aggression in Veterans
Posttraumatic stress disorder (PTSD) robustly predicts anger and aggression, and U.S. Iraq/Afghanistan-era combat Veterans report that treatment for anger and aggression is among their top priorities.
- Conditions
- Aggression, Anger, Posttraumatic Stress Disorder
- Trial name
- CBT-A (NCT02233517)
- Testing
- Cognitive Behavioral Therapy, Present Centered Therapy
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- VA Office of Research and Development
Attention Deficit Hyperactivity Disorder
Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study
This proposed research will use randomized control trial (RCT) methodology and compare micronutrients with placebo in 135 children with ADHD.
- Trial name
- MADDY (NCT03252522)
- Testing
- Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
- Where
- 3 sites in United States, Canada
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Eosinophilic Esophagitis (EoE)
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT05485779
- Testing
- AQ280
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Cardiovascular Diseases, Mood Disorders
Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior
Omega-3 fatty acids are a certain kind of fish fat that has recently been shown to have health benefits. This study will examine the effectiveness of fish oil supplementation for reducing the early signs of heart disease risk and…
- Conditions
- Cardiovascular Diseases, Mood Disorders, Inflammation
- Trial name
- NCT00663871
- Testing
- Fish Oil
- Where
- United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Healthy Male Subjects, Cardiovascular Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to assess the safety, tolerability…
- Trial name
- NCT02632526
- Testing
- AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Safety and Tolerability
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be evaluated in healthy adult subjects and adult…
- Trial name
- NCT03809052
- Testing
- GB1211
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB